Robert C. Smallridge
YOU?
Author Swipe
View article: Targeting CSF1R to overcome myeloid cell suppression in CART therapy
Targeting CSF1R to overcome myeloid cell suppression in CART therapy Open
Chimeric antigen receptor T (CART) cell therapy has shown unprecedented success in the treatment of hematological malignancies. However, the immunosuppressive tumor microenvironment of both solid and liquid tumors is a major barrier for CA…
View article: BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression
BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression Open
Introduction BRAFV600E mutation (BRAF mut ) is common in papillary thyroid cancer (PTC), and most patients have an excellent outcome. However, a TERT-promoter mutation (pTERT mut ) in the presence of BRAF mut (BRAF mut pTERT mut ) has been…
View article: Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer
Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer Open
Most thyroid cancer deaths are attributed to a subset of poorly differentiated, metastatic tumors. To improve treatment options for aggressive thyroid cancers, we developed a novel thyroid-stimulating hormone receptor (TSHR)-targeted chime…
View article: The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma Open
Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA from 329 regions of thyroi…
View article: The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma Open
Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA from 329 regions of thyroi…
View article: Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Supplementary Methods, Supplementary Figure and Table Legends
View article: Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Purpose:Thyroid cancer cell lines are valuable models but have been neglected in pancancer genomic studies. Moreover, their misidentification has been a significant problem. We aim to provide a validated dataset for thyroid cancer research…
View article: Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Supplementary Table S1. Cell line authentication by Short Tandem Repeat Profiling (STR) Supplementary Table S2. Full list of genetic variants identified by MSK-IMPACT sequencing Supplementary Table S3. Details for identified high-confidenc…
View article: Supplementary Figures S1-S10 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Supplementary Figures S1-S10 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Supplementary Figure S1. Copy number alteration profile for TERT locus in cell lines harboring homozygous TERT promoter mutations. Copy number changes are expressed as shades of red (gain) or blue (loss). Names of cell lines and log-ratio …
View article: Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Supplementary Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Supplementary Methods, Supplementary Figure and Table Legends
View article: Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Data from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Purpose:Thyroid cancer cell lines are valuable models but have been neglected in pancancer genomic studies. Moreover, their misidentification has been a significant problem. We aim to provide a validated dataset for thyroid cancer research…
View article: Supplementary Figures S1-S10 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Supplementary Figures S1-S10 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Supplementary Figure S1. Copy number alteration profile for TERT locus in cell lines harboring homozygous TERT promoter mutations. Copy number changes are expressed as shades of red (gain) or blue (loss). Names of cell lines and log-ratio …
View article: Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies Open
Supplementary Table S1. Cell line authentication by Short Tandem Repeat Profiling (STR) Supplementary Table S2. Full list of genetic variants identified by MSK-IMPACT sequencing Supplementary Table S3. Details for identified high-confidenc…
View article: Supplementary Figure Legends 1-3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure Legends 1-3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure Legends 1-3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
View article: Data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with …
View article: Supplemental Figure 1 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental Figure 1 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Supplemental Figure 1: RT-PCR assay for miR-30a expression in transfected cells by either miR-30a mimic (A) or miR-30a inhibitor (B) and theirand its corresponding controls.
View article: Supplemental Figure 3 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental Figure 3 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Supplemental Figure 3. Effect of LOX inhibition on metastasis in vivo. Treatment of mice before and after tail vein injection with 8505c cells reduced metastasis in vivo. BAPN treatment was initiated either 24 hours before (upper panel, fo…
View article: Supplemental Figure 1 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental Figure 1 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Supplemental Figure 1: RT-PCR assay for miR-30a expression in transfected cells by either miR-30a mimic (A) or miR-30a inhibitor (B) and theirand its corresponding controls.
View article: Supplementary Figure 2 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure 2 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure 2 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
View article: Supplemental data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Legends for supplemental figures
View article: Supplementary Figure 3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure 3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure 3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
View article: Data from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Data from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new therapeutic options are desperately needed. Previously, we showed that the high-affinity peroxisome proliferator–activated receptor γ (PPARγ) agoni…
View article: Supplemental data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Legends for supplemental figures
View article: Supplemental Figure 2 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental Figure 2 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Supplemental Figure 2. Images for each cell line shows cells that penetrated the Matrigel (invasion) and those that penetrated the insert's membrane (migration). 72 hours after transfection with miR-30a (A). LOX inhibition reduces cellular…
View article: Supplementary Figure 2 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure 2 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure 2 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
View article: Supplementary Figure 1 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure 1 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure 1 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
View article: Supplemental Figure 3 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental Figure 3 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Supplemental Figure 3. Effect of LOX inhibition on metastasis in vivo. Treatment of mice before and after tail vein injection with 8505c cells reduced metastasis in vivo. BAPN treatment was initiated either 24 hours before (upper panel, fo…
View article: Supplementary Figure 1 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure 1 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure 1 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
View article: Supplemental Figure 2 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Supplemental Figure 2 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression Open
Supplemental Figure 2. Images for each cell line shows cells that penetrated the Matrigel (invasion) and those that penetrated the insert's membrane (migration). 72 hours after transfection with miR-30a (A). LOX inhibition reduces cellular…
View article: Supplementary Figure Legends 1-3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Supplementary Figure Legends 1-3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Open
Supplementary Figure Legends 1-3 from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth